AlexLMX/iStock by way of Getty Photographs
- Jaguar Well being (NASDAQ: JAGX) shares fell on Wednesday after the botanical drug developer stated pivotal Part 3 trial knowledge for its anti-diarrhea drug Crofelemer will probably be out there on or earlier than July 23, 2024.
- The research, known as OnTarget, aimed to evaluate Crofelemer (versus placebo) as preventive remedy of most cancers treatment-associated diarrhea in grownup sufferers with strong tumors.
- “Third-party distributors who’re analyzing affected person knowledge from the OnTarget trial have recognized the important thing crucial steps required to share outcomes with Jaguar on or earlier than July 23, permitting us up to now the outcomes,” CEO Lisa Conte commented.
- Extra updates on Jaguar’s (JAGX) most cancers supportive care portfolio are additionally anticipated to be introduced at an investor occasion the corporate plans to host to launch Crofelemer knowledge.
-
In Could, Jaguar (JAGX) stated when it launched its first-quarter 2024 outcomes that OnTarget’s key outcomes could also be “imminent.”
